Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

• Main Authors: Binghe Xu (Author), Qingyuan Zhang (Author), Xichun Hu (Author), Qing Li (Author), Tao Sun (Author), Wei Li (Author), Quchang Ouyang (Author), Jingfen Wang (Author), Zhongsheng Tong (Author), Min Yan (Author), Huiping Li (Author), Xiaohua Zeng (Author), Changping Shan (Author), Xian Wang (Author), Xi Yan (Author), Jian Zhang (Author), Yue Zhang (Author), Jiani Wang (Author), Liang Zhang (Author), Ying Lin (Author), Jifeng Feng (Author), Qianjun Chen (Author), Jian Huang (Author), Lu Zhang (Author), Lisong Yang (Author), Ying Tian (Author), Hongyan Shang (Author)
• Format: Book
• Published: Elsevier, 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with HR + ABC that relapsed/progressed after ≥1 endocr...